Accelerating HCP Outreach in NSCLC Through Real-Time Biomarker Alerts

Therapy Area:

Oncology & Hematology

Product Stage:

Post-launch

Company Type:

Top 10 global pharmaceutical company

Location:

North America & Asia-Pacific

15 x

faster engagement

600 +

unique providers identified

900 +

therapy eligible patients

The challenge

The client needed to engage HCPs managing patients with biomarker-positive NSCLC, covering Biomarker A and Biomarker B, in near real time. A monthly data cadence was too slow for competitive outreach. Speed was critical if the therapy was to be considered before treatment decisions were made, particularly as the brand was not first to market and competed with multiple treatment options.

Business-critical issues included:

Delayed engagement due to monthly data cadence
Competitive pressure in the biomarker-driven therapy space
Missed opportunities for therapy adoption

External factors:

Fast-evolving NSCLC landscape
Importance of biomarker testing
Need for real-time outreach

The solution

Diaceutics introduced Signal, delivering daily real-time alerts to identify treating HCPs of Biomarker A and Biomarker B-positive patients diagnosed within the last 24 hours.

Key activities included:

Signal alerts delivered 5 days a week
Commercial teams engaged HCPs immediately after biomarker results became available
Supported faster outreach in a competitive treatment landscape

Collaboration model:

6-month pilot program

Why it matters

In a competitive NSCLC market, the opportunity to engage treating HCPs can narrow quickly once a biomarker result becomes available. Signal gives commercial teams visibility of relevant diagnostic events within 24 hours, helping them reach HCPs while treatment decisions are still being made. This creates more opportunity to support therapy consideration and reach eligible patients.

Achieved:

15x faster HCP engagement
600+ unique HCPs identified
900+ therapy-eligible patients identified

Testimonial

"The client reported that Signal enabled faster HCP engagement and improved therapy adoption."

About Diaceutics

At Diaceutics, our vision is Precision for All: a future where every eligible patient is identified, diagnosed and receives the right therapy at the right time.

For more than 20 years, we have helped biopharma companies overcome the diagnostic and commercialization barriers that stand between scientific innovation and patient impact. Today, we combine diagnostic intelligence, expert insight and targeted engagement to unlock the full potential of diagnostic-driven therapies—and more life for the patients they are designed to serve.